Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Algeta

Bayer symbol

Bayer bulks up in women’s health again with non-hormonal contraceptive deal

If approved candidate would become a first-in-category therapy

Bayer symbol

Bayer extends alliance with Evotec in women’s health

Five-year research agreement focuses on polycystic ovary syndrome

Bayer symbol

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

Significantly reduced the risk of hospitalisation or cardiovascular death

Bristol Myers Squibb logo

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Possible new treatment for difficult to treat cancer type

- PMLiVE

Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

Will likely face competition soon from rival Rozlytrek

- PMLiVE

New hires at Bayer, Eisai and Accord Healthcare

The latest movers in pharma

Roche Basel Switzerland

Roche undercuts price of Bayer cancer drug after winning FDA approval

Both drugs highly effective in small subset of patients

Bayer symbol

Bayer takes control of BlueRock stem cell joint venture

Deal values BlueRock at $1bn

- PMLiVE

Bayer taps Sensyne Health AI and real world data for cardiovascular research

Sensyne a ‘docking station’ for anonymised NHS patient data analysis

Bayer symbol

Bayer bags FDA nod for early prostate cancer drug darolutamide

new competition in the market

- PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list

Bayer symbol

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links